Basic Information
| LncRNA/CircRNA Name | MYU |
| Synonyms | VPS9D1-AS1 |
| Region | GRCh38_16:89711856-89718165 |
| Ensemble | ENSG00000261373 |
| Refseq | NR_036480 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | 2 | ||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, ChIP, Dual luciferase activity assay, Western blot |
| Sample | cell lines (Du145, PC3, 22Rv1, LNCaP) |
| Expression Pattern | up-regulated |
| Function Description | lncRNA MYU is significantly upregulated in prostate cancer tissues. MYU knockdown impaired prostate cancer cell growth and migration. lncRNA MYU was able to be transported into the extracellular milieu by means of exosomes. lncRNA MYU upregulated c-Myc by competitively binding miR-184 and then induced the proliferation of prostate cancer.Apparently, the methylation levels of histone H3 of the MYU promoter region in PCa tissues was signifcantly lower than those of adjacent normal tissues. |
| Pubmed ID | 30132573 |
| Year | 2018 |
| Title | Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis. |
External Links
| Links for MYU | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |